Found: 668
Select item for more details and to access through your institution.
Progressive multifocal leukoencephalopathy in association with siponimod treatment for secondary progressive multiple sclerosis: a case report.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
Spinal cord involvement in progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome.
- Published in:
- Journal of NeuroVirology, 2024, v. 30, n. 2, p. 208, doi. 10.1007/s13365-024-01213-y
- By:
- Publication type:
- Article
Progressive multifocal leukoencephalopathy associated with systemic lupus erythematosus: longitudinal observation of lymphocytes, JC virus in cerebrospinal fluid, and brain magnetic resonance imaging.
- Published in:
- Journal of NeuroVirology, 2024, v. 30, n. 2, p. 197, doi. 10.1007/s13365-024-01203-0
- By:
- Publication type:
- Article
Progressive multifocal leukoencephalopathy: MRI findings in HIV-infected patients are closer to rituximab- than natalizumab-associated PML.
- Published in:
- 2021
- By:
- Publication type:
- journal article
SARS-CoV2 Infection in a Multiple Sclerosis Patient Treated with Natalizumab - A Case Presentation.
- Published in:
- Acta Marisiensis. Seria Medica, 2020, v. 66, n. 3, p. 110, doi. 10.2478/amma-2020-0022
- By:
- Publication type:
- Article
Progressive Multifocal Leukoencephalopathy Presenting with Bilateral Myoclonus: A Case Report.
- Published in:
- Mediterranean Journal of Infection, Microbes & Antimicrobials, 2020, v. 9, p. 40, doi. 10.4274/mjima.galenos.2020.2020.6
- By:
- Publication type:
- Article
A case of IgG4-related disease associated with ulcerative colitis that was successfully treated with a JAK inhibitor.
- Published in:
- Modern Rheumatology Case Reports, 2024, v. 8, n. 2, p. 339, doi. 10.1093/mrcr/rxae025
- By:
- Publication type:
- Article
Neurological Disease-Affected Patients, including Multiple Sclerosis, Are Poor Responders to BKPyV, a Human Polyomavirus.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Progressive multifocal leukoencephalopathy after heart transplantation: 4 years of clinically stable infection on low-dose immunosuppressive therapy.
- Published in:
- 2017
- By:
- Publication type:
- Case Study
"Burnt‐out" progressive multifocal leukoencephalopathy in idiopathic CD4<sup>+</sup> lymphocytopenia.
- Published in:
- Neuropathology, 2021, v. 41, n. 6, p. 484, doi. 10.1111/neup.12773
- By:
- Publication type:
- Article
Progressive multifocal leukoencephalopathy in idiopathic CD4<sup>+</sup> lymphocytopenia: A case report and review of literature.
- Published in:
- Neuropathology, 2019, v. 39, n. 6, p. 467, doi. 10.1111/neup.12599
- By:
- Publication type:
- Article
The Role of Gut Microbiome in the Pathogenesis of Multiple Sclerosis and Related Disorders.
- Published in:
- Cells (2073-4409), 2023, v. 12, n. 13, p. 1760, doi. 10.3390/cells12131760
- By:
- Publication type:
- Article
A Commercial Probiotic Induces Tolerogenic and Reduces Pathogenic Responses in Experimental Autoimmune Encephalomyelitis.
- Published in:
- Cells (2073-4409), 2020, v. 9, n. 4, p. 906, doi. 10.3390/cells9040906
- By:
- Publication type:
- Article
Natalizumab Treatment for Relapsing Multiple Sclerosis Stabilises Normal-Appearing White Matter Microstructure: A One-Year Prospective Ultra-High-Field Quantitative Imaging Study.
- Published in:
- Brain Sciences (2076-3425), 2023, v. 13, n. 10, p. 1464, doi. 10.3390/brainsci13101464
- By:
- Publication type:
- Article
Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION―A 2-Year, Multicenter, Observational, Cohort Study.
- Published in:
- Brain Sciences (2076-3425), 2022, v. 12, n. 2, p. 215, doi. 10.3390/brainsci12020215
- By:
- Publication type:
- Article
Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study.
- Published in:
- Frontiers in Immunology, 2023, v. 14, p. 1, doi. 10.3389/fimmu.2023.1086028
- By:
- Publication type:
- Article
Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.996469
- By:
- Publication type:
- Article
Epstein-Barr Virus and multiple sclerosis in a Spanish cohort: A two-years longitudinal study.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.991662
- By:
- Publication type:
- Article
Antibody-mediated cell depletion therapies in multiple sclerosis.
- Published in:
- Frontiers in Immunology, 2022, v. 12, p. 1, doi. 10.3389/fimmu.2022.953649
- By:
- Publication type:
- Article
Divergent complement system activation in two clinically distinct murine models of multiple sclerosis.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 01, doi. 10.3389/fimmu.2022.924734
- By:
- Publication type:
- Article
Case report: Variant-specific pre-exposure prophylaxis of SARS-CoV-2 infection in multiple sclerosis patients lacking vaccination responses.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 01, doi. 10.3389/fimmu.2022.897748
- By:
- Publication type:
- Article
Immunomodulatory effects of microbiota-derived metabolites at the crossroad of neurodegenerative diseases and viral infection: network-based bioinformatics insights.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.843128
- By:
- Publication type:
- Article
Killing Two Birds With One Stone: Effective Control of Both Non-Small Cell Lung Cancer and Progressive Multifocal Leukoencephalopathy With Atezolizumab, A Case Report.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.889148
- By:
- Publication type:
- Article
IFN-β Deficiency Results in Fatal or Demyelinating Disease in C57BL/6 Mice Infected With Theiler's Murine Encephalomyelitis Viruses.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.786940
- By:
- Publication type:
- Article
Psoriasiform dermatitis following ocrelizumab in relapsing-remitting multiple sclerosis: Case report and literature review.
- Published in:
- Multiple Sclerosis Journal, 2024, v. 30, n. 7, p. 893, doi. 10.1177/13524585241232277
- By:
- Publication type:
- Article
Natalizumab reduces loss of gray matter and thalamic volume in patients with relapsing-remitting multiple sclerosis: A post hoc analysis from the randomized, placebo-controlled AFFIRM trial.
- Published in:
- Multiple Sclerosis Journal, 2024, v. 30, n. 6, p. 687, doi. 10.1177/13524585241235055
- By:
- Publication type:
- Article
Responsiveness to pembrolizumab in severe early-onset natalizumab associated PML-IRIS in patient with relapsing-remitting multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2024, v. 30, n. 6, p. 760, doi. 10.1177/13524585241231655
- By:
- Publication type:
- Article
Susceptibility-based imaging aids accurate distinction of pediatric-onset MS from myelin oligodendrocyte glycoprotein antibody-associated disease.
- Published in:
- Multiple Sclerosis Journal, 2023, v. 29, n. 14, p. 1736, doi. 10.1177/13524585231204414
- By:
- Publication type:
- Article
Rethinking vaccination in multiple sclerosis: The way forward.
- Published in:
- Multiple Sclerosis Journal, 2023, v. 29, n. 11/12, p. 1351, doi. 10.1177/13524585231204126
- By:
- Publication type:
- Article
Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light.
- Published in:
- Multiple Sclerosis Journal, 2023, v. 29, n. 10, p. 1229, doi. 10.1177/13524585231188625
- By:
- Publication type:
- Article
Evaluating the efficacy and safety of transitioning patients with multiple sclerosis from natalizumab to ocrelizumab (OCTAVE).
- Published in:
- Multiple Sclerosis Journal, 2023, v. 29, n. 8, p. 956, doi. 10.1177/13524585231175284
- By:
- Publication type:
- Article
Safety of COVID-19 vaccines in multiple sclerosis: A systematic review and meta-analysis.
- Published in:
- Multiple Sclerosis Journal, 2023, v. 29, n. 4/5, p. 585, doi. 10.1177/13524585221150881
- By:
- Publication type:
- Article
Comparative effectiveness in multiple sclerosis: A methodological comparison.
- Published in:
- Multiple Sclerosis Journal, 2023, v. 29, n. 3, p. 326, doi. 10.1177/13524585231151394
- By:
- Publication type:
- Article
Management approach including pembrolizumab for fingolimod-associated progressive multifocal leukoencephalopathy in a patient with relapsing-remitting multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2023, v. 29, n. 2, p. 301, doi. 10.1177/13524585221137279
- By:
- Publication type:
- Article
Immune checkpoint inhibitors: A potential bright spot in the treatment of progressive multifocal leukoencephalopathy in multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2023, v. 29, n. 2, p. 306, doi. 10.1177/13524585221137275
- By:
- Publication type:
- Article
Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6 years.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 13, p. 2137, doi. 10.1177/13524585221079598
- By:
- Publication type:
- Article
Extended dosing of monoclonal antibodies in multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 13, p. 2001, doi. 10.1177/13524585211065711
- By:
- Publication type:
- Article
All anti-CD20 monoclonal antibodies have similar efficacy and risks: No.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 12, p. 1845, doi. 10.1177/13524585221103729
- By:
- Publication type:
- Article
ECTRIMS 2022 – LB ePoster.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, p. 984, doi. 10.1177/13524585221126910
- Publication type:
- Article
ECTRIMS 2022 LB Poster.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, p. 956, doi. 10.1177/13524585221126909
- Publication type:
- Article
ECTRIMS 2022 – Oral Presentations.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, p. 3, doi. 10.1177/13524585221123685
- Publication type:
- Article
ECTRIMS 2022 – Late Breaking Oral Presentations.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, p. 946, doi. 10.1177/13524585221126908
- Publication type:
- Article
Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: YES.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 8, p. 1173, doi. 10.1177/13524585221088734
- By:
- Publication type:
- Article
Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: No.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 8, p. 1175, doi. 10.1177/13524585221091404
- By:
- Publication type:
- Article
Low-dose rituximab should be used for treating MS in resource-limited settings: Commentary.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 7, p. 1032, doi. 10.1177/13524585221098612
- By:
- Publication type:
- Article
Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing—Commentary.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 5, p. 695, doi. 10.1177/13524585211067708
- By:
- Publication type:
- Article
Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing: NO.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 5, p. 693, doi. 10.1177/13524585211064441
- By:
- Publication type:
- Article
Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing—"Yes".
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 5, p. 691, doi. 10.1177/13524585211055593
- By:
- Publication type:
- Article
Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 1, p. 102, doi. 10.1177/13524585211010097
- By:
- Publication type:
- Article
Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 1, p. 7, doi. 10.1177/1352458520949158
- By:
- Publication type:
- Article